{"name":"Maruho Co., Ltd.","slug":"maruho-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"CLS001","genericName":"CLS001","slug":"cls001","indication":"Other","status":"phase_2"},{"name":"CLS001 Topical Gel","genericName":"CLS001 Topical Gel","slug":"cls001-topical-gel","indication":"Other","status":"phase_2"},{"name":"M516102","genericName":"M516102","slug":"m516102","indication":"Other","status":"phase_2"},{"name":"M518101","genericName":"M518101","slug":"m518101","indication":"Other","status":"phase_3"},{"name":"Omiganan 1% and Imiquimod","genericName":"Omiganan 1% and Imiquimod","slug":"omiganan-1-and-imiquimod","indication":"Other","status":"phase_1"},{"name":"Omiganan 2.5% and Imiquimod","genericName":"Omiganan 2.5% and Imiquimod","slug":"omiganan-2-5-and-imiquimod","indication":"Other","status":"phase_1"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Mitchga","genericName":"NEMOLIZUMAB","slug":"nemolizumab","indication":"Pruritus associated with atopic dermatitis","status":"marketed"},{"name":"CLS006","genericName":"CLS006","slug":"cls006","indication":"Investigational dermatological indication (specific indication not publicly disclosed)","status":"phase_3"},{"name":"CLS006 Vehicle","genericName":"CLS006 Vehicle","slug":"cls006-vehicle","indication":"Vehicle formulation for topical dermatological agents (specific indication depends on active drug)","status":"phase_3"},{"name":"Vehicle Topical Gel","genericName":"Vehicle Topical Gel","slug":"vehicle-topical-gel","indication":"Treatment of various skin conditions","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CLS001 (Omiganan)","genericName":"CLS001 (Omiganan)","slug":"cls001-omiganan","indication":"Atopic dermatitis with bacterial colonization","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Furosemide Topical Gel","genericName":"Furosemide Topical Gel","slug":"furosemide-topical-gel","indication":"Edema","status":"phase_2"}]}],"pipeline":[{"name":"Mitchga","genericName":"NEMOLIZUMAB","slug":"nemolizumab","phase":"marketed","mechanism":"Nemolizumab works by binding to the interleukin-31 receptor subunit alpha, blocking the action of interleukin-31 and reducing inflammation and itching.","indications":["Pruritus associated with atopic dermatitis"],"catalyst":""},{"name":"CLS001","genericName":"CLS001","slug":"cls001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CLS001 (Omiganan)","genericName":"CLS001 (Omiganan)","slug":"cls001-omiganan","phase":"phase_3","mechanism":"Omiganan is an antimicrobial peptide that disrupts bacterial cell membranes by binding to lipopolysaccharides and lipoteichoic acids, leading to bacterial cell death.","indications":["Atopic dermatitis with bacterial colonization","Impetigo and other skin and soft tissue infections"],"catalyst":""},{"name":"CLS001 Topical Gel","genericName":"CLS001 Topical Gel","slug":"cls001-topical-gel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CLS006","genericName":"CLS006","slug":"cls006","phase":"phase_3","mechanism":"CLS006 is a topical agent developed for dermatological conditions, likely targeting inflammatory or proliferative skin pathways.","indications":["Investigational dermatological indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"CLS006 Vehicle","genericName":"CLS006 Vehicle","slug":"cls006-vehicle","phase":"phase_3","mechanism":"CLS006 Vehicle is a topical formulation vehicle designed to enhance drug delivery and penetration through the skin.","indications":["Vehicle formulation for topical dermatological agents (specific indication depends on active drug)"],"catalyst":""},{"name":"Furosemide Topical Gel","genericName":"Furosemide Topical Gel","slug":"furosemide-topical-gel","phase":"phase_2","mechanism":"Furosemide acts as a loop diuretic by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle.","indications":["Edema","Hypertension"],"catalyst":""},{"name":"M516102","genericName":"M516102","slug":"m516102","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"M518101","genericName":"M518101","slug":"m518101","phase":"phase_3","mechanism":"M518101 is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions.","indications":[],"catalyst":""},{"name":"Omiganan 1% and Imiquimod","genericName":"Omiganan 1% and Imiquimod","slug":"omiganan-1-and-imiquimod","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Omiganan 2.5% and Imiquimod","genericName":"Omiganan 2.5% and Imiquimod","slug":"omiganan-2-5-and-imiquimod","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vehicle Topical Gel","genericName":"Vehicle Topical Gel","slug":"vehicle-topical-gel","phase":"phase_3","mechanism":"Vehicle Topical Gel is a topical formulation that serves as a vehicle for delivering active pharmaceutical ingredients.","indications":["Treatment of various skin conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNTlNUMDVON0lvSzhreTBCd04xVzFyRk5rZ2VKYUxxWTA1YWpkQU8yS1FNakotc3B5MkkybUdhc2s2XzNtR2FFWndOaHZFb0NMbzNRbUoteVEyV0hUTjdwZ3BmN3dwUzAxVUdWck5JOWNCMWdBWEs3RUNFUjlwVkVGenZ0Sk5SanR6SkRLaDZhdU9zNEtHR3c?oc=5","date":"2026-04-06","type":"earnings","source":"openPR.com","summary":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight - openPR.com","headline":"Common Warts Market: Expanding Revenue Landscape to 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNLUpqeFlkaDBWQU9oQVdGcG1TWFRKQmtaQnprUUNMOGg4SUU2eGxTVE1yRkw3TWtaXzJ1akIyb2ttaFNqV2d2clFBOGR2cGdOVnBIWHN6dXNORngwOTRiM2ZfZGk5TTN0b0s0V0phM1NtbGkzR250d2VUOTlXbzZCNllVZmlWaXRXSFF1b0JVcEVJYWdmQmoxUWl0T3lYVmNzS3k1SWFCWVd5V2pQZ3o3US1HTkNfS3hpYmdXNFFOTQ?oc=5","date":"2025-10-24","type":"deal","source":"BioSpace","summary":"Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd. - BioSpace","headline":"Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOd25tNjNZTTJLVWdoM1Z1NkpFblJKQm15M3R2VmZfdE55SklSVWJ2WWVIek5GRzNZUGM2OVlwZExuR2hwU0pWWXVmMVN5VGlYQTdWc1EzWU9MWjMzZVJ0UEZBYzFtRDc3ZFNVa2JuNjZsZnVFZklYUGVZa1ZCYjY0dU5tMFFwYnh6Zk42dzRHRkNjb0Q2Sm5Yc1MtZU83VnR3LW5zTGRsaTBqSzNiNk5HYmZPVFVQTHE1b0N1akNzUDVkWHQ2YmR6V3VxNVMzVFJROGo4NDkwRE9zMUdwT3p1THVhcFZsdjRaNTZwdzFzdnpqXzFOcDNMQkxyODlsTHUwOW5aRXNfQVlzSEhVc1htRVJYbkdYZmpUS3RRcFd4RkVXa3VMaGppTkVHSWc0N25tR1pBQnQ5VjZES0ZBVmRvaGlFUlk?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"Atopic Dermatitis Drugs Market to Grow by USD 6.2 Billion (2024-2028), Driven by High Prevalence of the Condition, AI-Powered Report Explores Market Evolution - Technavio - PR Newswire","headline":"Atopic Dermatitis Drugs Market to Grow by USD 6.2 Billion (2024-2028), Driven by High Prevalence of the Condition, AI-Po","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOcGt6ZWEwTkxuUU1OQ0NvdDJLSFR6bkpXaWFaeXlvZFR4d29TV2hsbk5zV2hMX3V4NUZ3ekRkb21pR3JHVHlYb1NyTXBiUklNTnNSV21fT3JpQVYyRV9rQ0l4UUZzUU5Id1Rfc0hxOXlnMV84Y21TZ1NEdUh6MU92NDZCVUd4aDg1TlE?oc=5","date":"2024-02-20","type":"pipeline","source":"Packaging World","summary":"Innovative New Pharma Packaging at PACK EXPO - Packaging World","headline":"Innovative New Pharma Packaging at PACK EXPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPN25wOWkzelQzRHE2OERfdDZYNGhCWElLanZmTkZ3Z0h3WmJoLUw5UlQ1c2hZb1RibUJlVTZVQ1hEMWVzS19ja0xyeXhjZUR0ZF9BYUZiYnliUFZRVlR1ZmZOUmtLbjVnbHEyWGw2YTZVd0pFRzNReE5tZFhPTTcySW5qTHp0RjlnakFyV2kyWEs4ME5xT2ZqOVZrbVY3U2M4ZzV0UlhKQVotMl9wdHg0TEdRckZEdFE?oc=5","date":"2023-10-18","type":"deal","source":"BioWorld News","summary":"GI Innovation inks second GI-301 licensing deal with Japan’s Maruho for $220M - BioWorld News","headline":"GI Innovation inks second GI-301 licensing deal with Japan’s Maruho for $220M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOc3I0eHNjQ2pTM3pQQkFLcHMzck5FNkhjQ3RVVnQ0SkxUSGdSb3ViTzVaNmJRbERnU3lQSlFJc2RWRGx4V01USmdQbi1mN0luRTEtdV9TckZwcTRhc0Rvb3lCSDVUTFVDT2taTktZdFJ0QkdNZDhRSXBOY2ZRTDlQT0xNVGxUN0xXZ0JpbmNCcw?oc=5","date":"2023-05-27","type":"deal","source":"San Diego Business Journal","summary":"Nielsen BioSciences Inks $100M Deal - San Diego Business Journal","headline":"Nielsen BioSciences Inks $100M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQcTdlVk05eHVRV201Y1JVM3VwQzJrUVhrakFWeXFNSkl4aWhYZXM1RHdmQTl4LTNhaUFxeVB1cVM3ZkEtaVdPZ1lYSG5pU0J4NE1sN2hDVlViYjZrZmtocjBBeE90OWV2dlE1dHYtSTVzY0pOUXJVYVJubGh0S183VXp3alh2ckRzZ2ZQSFZsNTZTVFY5ZnVQclFLWV8tYUZlZ1dUemNsX2VXREQ3dE1wY3pmTm9CY2lBd0hNSFdLY0dUZUdyVUdWUmJqOGV4MHgwd3c?oc=5","date":"2023-05-25","type":"pipeline","source":"Healio","summary":"Nielsen enters agreement with Maruho for marketing rights to verruca vulgaris treatment - Healio","headline":"Nielsen enters agreement with Maruho for marketing rights to verruca vulgaris treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOM1JsNG14bTE0QXVVT2kzQkM0MkFjdzUxRDNvZzU2cm0xYWMzRE45YUdkb2Zpd3hfaXMwY2lCaDBJM05wV0hreEtYS1N1MVE0OHoxWXpCcldEaERMSFIwLWpQcUY5czc2WUEtd1RqS2F0eE11Tzd0Q3VhLUN4cUt3ZU1ZMDNfSEZKanRuNHJvc0M5a2Eza1RBMW43bFE4cHpXMWRtUVZUczMySFRacUpuOUlvRWtrcjFob0l4ZXFIT0JJTk5XY0FwRzlSRGlCYW1yOVFaOVREYU1Mc2xDQ1ZiSHNiRWt5aVliZTFWdnhiWHlUQ1NuT1FwLU92d0tqVFBYVnhFZlhrTXhZN3pU?oc=5","date":"2022-12-19","type":"pipeline","source":"PR Newswire","summary":"Herpes treatment market to grow by 4.05% Y-O-Y in 2023; Increasing prevalence of herpes infection will drive growth - Technavio - PR Newswire","headline":"Herpes treatment market to grow by 4.05% Y-O-Y in 2023; Increasing prevalence of herpes infection will drive growth - Te","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOUllaNHdIMHAyb1Q1aklmWTE3ZlI1a0pBaXRaN2lOUnYySGJmTmNlMXRoSnlwcmQ2Q3hrSWJOM1ViYXlraDVkc3drdjZuVS0xeXZnQll0SHF1R016Qm9LLWVVOWVDZHF5M19lVUFjU3BjT2gzU3RfY3ZSVExoWUlCaUl4VUxSX3JzVUdHY041YklsMUNFcmp1clZnbEVyYi1zNGtDc1E0X2Z4WmVjRzc3dzMzcjR3QkZsOVRBUVdkdW1OZTZmY2U1ekZjV3ltYml4YnRobVlUaFppTEtfbGsxT0ZpMzB0OE4xMVBQMkM0UEx0NXJtUE1MbUNfZmpSVFpFbmFQVkUxN0xaNHRGT25UWXJsUFIxSDRIMk5id185S1p2ZmhfczFxRkF4bE9ja1Y1RWNrbkcxRjIwLVdBVGl5cVo2TU5ET0Nqdk55QXJyY3lESlZyNzRv?oc=5","date":"2022-11-22","type":"earnings","source":"PR Newswire UK","summary":"With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Drugs - Market Revenue to Cross USD 11 Billion by 2027 - Arizton - PR Newswire UK","headline":"With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Dru","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNdHJ6anpPdng4dkZic2hSemFJSEFRNG9TNnNEZ3UwcTh6U1BQNzloYTlNakZrZVJpdl91d2JkQnByb2lubENGUDVGb1FuUWFqTEllcjQwZmpaY2xIMjBDUXh5X1o4MUo4aU16TXNWZGp1Q2g3NFBjTUc3NE81blNzQmlTOXhMcUZkVDN3aw?oc=5","date":"2019-07-18","type":"pipeline","source":"Contract Pharma","summary":"MHI Appoints National Accounts Manager - Contract Pharma","headline":"MHI Appoints National Accounts Manager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9ITmxSZnQxajRoNVQtenNZaEtfeFRCVGlzeDdGaHNkR3pyU051VzVzNzVSay1Ec1J6dVgxaUF6US1GbUxOYVduVlA4LW5zOFM5Tk5uNmFQSzN5MVk?oc=5","date":"2011-03-02","type":"pipeline","source":"Nitto Denko Corporation","summary":"Nitto Europe (français) | Hokunalin® Tape (tulobuterol patch), a long-acting transdermal bronchodilator,is now in new packages printed with the content on the tape surface and the barcode on the pouch","headline":"Nitto Europe (français) | Hokunalin® Tape (tulobuterol patch), a long-acting transdermal bronchodilator,is now in new pa","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"marketed":1,"phase_2":4,"phase_3":5,"phase_1":2},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}